HOWSON AND HOWSON

PAGE 04/04

PTO/SB/08A (08-03) Approved for use through 07/31/2006, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE d to a collection of information unless it contains a valid OMB control number. Under the Peperwork Reduction Act of 1995, no persons are required to respon Complete if Known ... Substitute for form 1449/PTO Application Number 10/767,813 Filing Dale January 29, 2004 INFORMATION DISCLOSURE First Named Inventor Zhang et al. STATEMENT BY APPLICANT. 1614· Examiner Name D. C. Jones TA JOH SETTON (Use as many sheets as necessary) Sheet U. S. PATENT DOCUMENTS Pages, Columns, Lines, Where Relevant Passages or Relevant - Name of Patentee or Publication Date
MM-DD-YYYY Cite No. Document Number Applicant of Cited Document Number-Kind Code^{2 (Floren)} us- 6,566,372 -ĪΗ 05-20-2003 Zhi et al. ^{US-} 2003/0130505-A1 Zhi et al. 07-10-2003 US. US. ÚŚ. UŠ US HR. IIS. US-US-US บร US-IIS. US-FOREIGN PATENT DOCUMENTS Pages, Courns, Unes, Where Relevant Passages Foreign Patent Document Date MM-DD-YYYY Applicant of Cited Document tolfinla* No. Or Relevant Figures Appear Country Code⁰ "Number ¹ "Kind Code⁰ (if known) Zhi et al. WO-01/15108-A2 03-08-2001 1EP IN Considered See Kinds Codes of

*EXAMINER: Initial if reference considered. Whether or not cripton is in conformance with MPEP 609. Draw line through distant if not tryconformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes or USPTO Patent Documents at www.upros.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO. Standard ST.3). *For Japanese petent documents, the indication of the year of the reign of the Emperor must precede the sental-number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English tanguage Translation to attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97, and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the inclividual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND.

TO: Commissionar for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9189 (1-800-788-9199) and select option 2.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

to a collection of information unless it contains a valid OMB control number. the Peperwork Reduction Act of 1995, no persons are required to rea

Substitute for form 1449/PTO

Sheet 1

A PROPERTY AND PARTY.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known						
Application Number	10/767,813					
Filing Date	January 29, 2004					
First Named Inventor	Zhang et al.					
Art Unit	onassigned UU					
Examiner Name	unassigned BETON, TE					
Attorney Docket Number	AHPWA1DUSA					

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No. ¹		MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
/int	AA	Number-Kind Code ^{2 (4 trount)} US- 3,526,621	11-01-1970	Bernardi	
July 1	AB	^{US-} 3,635,941	01-18-1972	Weaver	
Let	AC	US- 3,635,964	01-18-1972	Skorcz	
18	AD	^{US-} 3,917,592	11-04-1975	Kobzina	
166	AE	^{US-} 4,093,730	06-06-1978	Butti	
EB	AF	^{US-} 4,440,785	04-03-1984	Walsh	
15/3	AG	US-4,617,302	10-14-1986	Robertson	
166	AH	US- 4,666,913 .	05-19-1987	Kuhla	
184	AI	^{US-} 4,670,566	06-02-1987	Walsh	
183	AJ	US- 4,721,721	12-26-1988	Kuhla	
TEB	AK	^{US-} 4,792,561	12-20-1988	Walker	
TEB	BA	^{US-} 4,822,794	04-18-1989	Spada	
TeB	ВВ	^{US-} 4,831,027	05-16-1989	Narr .	· · · · · · · · · · · · · · · · · · ·
TEB	ВС	us- 4,853,473	08-01-1989	Fischer	
UB	BD	us- 4,933,336	06-12-1990	Martin	
TEB	BE	US- 5,007,952	04-16-1991	Kume	
168	BF	^{US-} 5,171,851	12-15-1992	Kim	
TEB	BG	^{US-} 5,182,282	01-26-1993	Clemence	
TEN	≱вн	^{US-} 5,246,989	09-21-1993	Iwamoto	

		FORE	IGN PATENT DOCU	IMENTS		,
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	امرا
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
NEB	AL	DE-3,633,861	04-07-1988	Narr		
PEB	AM	DE-4,330,234	03-09-1995	Chwalisz		
180	AN	DE-4,344,463	06-29-1995	Stockemann		
103		EP-022,317	01-14-1981	Watanabe		Щ
163		EP-166,533	04-11-1990	Campbell	<u> </u>	$ldsymbol{ldsymbol{ldsymbol{eta}}}$
		EP-208,510	01-14-1987	Kadin		لسل

. •			
Examiner Signature	11. 6 h	Date Considered	8/14/07
Signature			0 -

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation find in conformance and not considered. Include copy of this form with mext communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspio.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, use to process an application. Confidentiality the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Tradamark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork	k Reduction Act of 1995, no persons are required to	respond to a collection of informati	tion unless it contains a valid OMB control nur	<u>npe</u>		
	Substitute for form 1449/PTO		Complete if Known			
Substitute for form	1449/P10	Application Number	10/767,813			
WITCHIA TION DIOOLOGUEE		Filing Date	January 29, 2004			
	ATION DISCLOSURE	First Named Inventor	Zhang et al.			
STATEM	ENT BY APPLICANT	Art Unit	unessigned1614			
(Use a	(Use as many sheets as necessary)	Examiner Name	unassigned BETTON, TE			
Shoot 12	of 15	Attorney Docket Number	AHPWA1DUSA			

Sheet

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentize or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
743	ВІ	US- 5,300,655	04-05-1994	Ehrgott	
127	BJ	US- 5,414,088	05-09-1995	von der Saal	
100	вк	us- 5,447,928	11-05-1995	Williams	
TEB	CA	^{US-} 5,453,516	09-26-1995	Fischer	
TEB	СВ	^{US-} 5,475,020	12-12-1995	Johnson	
TEB	СС	US- 5,519,021	05-21-1996	Young	
186	CD	US- 5,521,166	05-28-1996	Grubb	<u> </u>
306	CE	us- 5,552,412	09-03-1996	Cameron	
TEB	CF	^{US-} 5,565,483	10-15-1996	Hewawasam	
TEB	CG	us- 5,576,330	11-19-1996	Buzzetti	
188	СН	^{US-} 5,659,046	08-19-1997	Kameswaran	
TES	Ci	US- 5,681,817	10-28-1997	Hodgen	
£83	CJ	^{US-} 5,688,808	11-18-1997	Jones	
183	СК	us- 5,688,810	11-18-1997	Jones	
1213	DA	us- 5,693,646	12-02-1997	Jones	<u> </u>
TEB	DB	us- 5,693,647	12-02-1997	Jones	
EB	DC	US- 5,696,127	12-02-1997	Jones	
TEB	DD	^{US-} 5,696,130	12-02-1997	Jones	
TEX		^{US-} 5,696,133	12-02-1997	Jones	*

		FORE	IGN PATENT DOCU	MENTS		
Examiner Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	اہا	
TITLE OF	_	Country Code ³ "Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Ľ
~~	BL	EP-311,135	04-12-1989	Ganzer		
TEX TOB	ВМ	EP-385,850	09-05-1990	Bru-Magniez	<u> </u>	
TEB	BN	EP-454,330	10-30-1991	Hara		
TEB	во	EP-483,077	09-27-1991	Fraschini		
183	BP	EP-510,235	10-28-1992	Kim		
		EP-535,529	09-24-1992	Takahashi		

			Date			~~
Examiner		1 1	1	1 01	1011	K - /
Signature		16	Consi		77/	J - F
O'ghata.	/.					- (

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this/form with next of memory of this/form with next of memory of this/form with next of the policiant. Applicant's unique citation designation number (optionally See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CER 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, use using attending, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AHPWA1DUSA

Considered

PTO/SB/08A (08-03)
Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/767,813 January 29, 2004 Filing Date INFORMATION DISCLOSURE First Named Inventor Zhang et al. STATEMENT BY APPLICANT unassigned 644 Art Unit (Use as many sheets as necessary) **Examiner Name**

Attorney Docket Number

Sheet	3	of 115		Allomey Docket Homoer PATT VV	
			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ren	DF	^{US-} 5,719,136	02-17-1998	Chwalisz	
log	DG	^{US-} 5,733,902	03-31-1998	Schneider	
TIEB	DH	us- 5,808,139	09-15-1998	Pathirana	
100	DI	^{US-} 5,874,430	02-23-1999	Christ	
148	DJ	^{US-} 6,013,652	01-11-2000	Maccoss	
FB	DK	^{US-} 6,077,840	06-20-2000	Kurihara	
10%	EA	US- 6,153,622	11-28-2000	Cameron	
FY3	EB	^{US-} 6,204,286	03-20-2001	Cameron	
TEB	EC	^{US-} 6,306,851	10-23-2001	Santilli	
Tek	ED	us- 6,319,912	11-20-2001	Grubb	
TEB	EE	^{US-} 6,329,416	12-11-2001	Grubb	
1EB	EF	^{US-} 6,339,098	01-15-2002	Collins	
TEB	EG	^{US-} 6,355,648	03-12-2002	Fensome	
TEB	EH	US- 6,358,947	03-19-2002	Zhi	
TEL	EI	us- 6,358,948	03-19-2002	Zhang	
TEB	EJ	us- 6,369,056	04-09-2002	Zhang	
TEB	EK	^{US-} 6,380,178	04-30-2002	Grubb	
TEB	FA	^{US-} 6,380,235	04-30-2002	Zhang	
Tel	FB	^{US-} 6,391,907	05-21-2002	Fensome	

		FOREIC	GN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	70
		Country Code ³ "Number ⁴ "Kind Code ⁸ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
183	CL	EP-947,507	10-06-1999	Kurihara		
TEB	СМ	EP-978,279	02-09-2000	Roth		\blacksquare
		JP-63112584	05-17-1988	Tatsu		\blacksquare
		RU-2067576-C1	10-10-1996	Clemence		\square
183	СР	HU-194842B	03-28-1988	Narr		lacksquare
EB	CQ	HU-P9600165-A	01-28-1997	Levi.	<u> </u>	لـــا

Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in oonlymance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of Information Is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/767,813 Filing Date January 29, 2004 INFORMATION DISCLOSURE First Named Inventor Zhang et al. STATEMENT BY APPLICANT Art Unit unassigned 614 Hunassigned BETTON (Use as many sheets as necessary) **Examiner Name**

AHPWA1DUSA Attorney Docket Number

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (F known)			1.90.00,4
1/1/2	FC	^{US-} 6,399,593	06-04-2002	Grubb	
488	FD	^{US-} 6,407,101	06-18-2002	Collins	
183	FE	US-6,417,214	07-09-2002	Ullrich	
768	FF	^{US-} 6,423,699	07-23-2002	Grubb	
198	FG	^{US-} 6,436,929	08-20-2002	Zhang	
133	FH	^{US-} 6,441,019	08-27-2002	Santilli	
TEB	FI	US- 6,441,193	08-27-2002	Cameron	
TEB	FJ	US- 6,444,668	09-03-2002	Grubb	
TEB	FK	^{US-} 6,462,032	10-08-2002	Grubb	
TEB	GA	^{US-} 6,498,154	12-24-2002	Grubb	
1883	GB	^{US-} 6,503,939	01-07-2003	Grubb	
TEB	GC	^{US-} 6,509,334	01-21-2003	Zhang	
1483	GD	^{US-} 6,521,657	02-18-2003	Fensome	
-FR	GE	us-6,544,970	04-08-2003	Grubb	
408	GF	us-6,566,358	05-20-2003	Zhang	
TEB	GG	us- 6,583,145	06-24-2003	Fensome	
RE	GH	^{US-} 6,562,857	05-13-2003	Collins	
TEB	GI	^{US-} 6,608,068	08-19-2003	Fensome	
- V	GJ	^{US-} 6,693,103	02-17-2004	Zhang	

		FORE	IGN PATENT DOCL	IMENTS		,
Examiner Cit		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	٠,
1110.010		Country Code ³ "Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	<u> </u>
(B)	DL	HU-P9800472-A	06-28-1999	Heinisch		
10B	DM	RU-2100359	12-27-1997	Kovelman		┡
183	DN	RU-2130020	05-10-1999	Pol		<u>L</u>
1815	DO	RU-2130454	05-20-1999	Kameron		┡
TES	DP	RU-213462	08-10-1999	Kameswaran		╙
		RU-2186775	08-10-2002	Jang		<u> </u>

Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (detional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

Examiner

Date

Considered

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uncluding gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Petents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to re

Substitute for form 1449/PTO

Sheet 5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/767,813			
Filing Date	January 29, 2004			
First Named Inventor	Zhang et al.			
Art Unit	unassigned 1014			
Examiner Name	unassigned BETTON, T.E.			
Attorney Docket Number	AHPWA1DUSA			

			U. S. PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (f brown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
400	GК	US- 6,713,478	03-30-2004	Zhang	
1235	HA	US- 2001-0025051-A1	09-27-2001	Cameron	
100	НВ	US- 2002-0169198-A1	11-14-2002	Fensome	•
106	нс	US- 2003-0158182-A1	08-21-2003	Fensome	
TEN	HD	US- 2003-0220388-A1	11-27-2003	Fensome	
Tib	HE	^{US-} 2003-0225109-A1	12-04-2003	Fensome	
408	HF	us- 2002-0115853-A1	08-22-2002	Zhang	
1728	HG	US- 2002-0151531-A1	10-17-2002	Grubb	
128	НН	US- 2003-0008909-A1	01-09-2003	Ullrich	
108	н	US- 2003-0045511-A1	03-06-2003	Grubb	
TEB	HJ	US- 2003-0092711-A1	05-15-2003	Zhang	<u> </u>
18	нк	^{US-} 4,518,597	05-21-1985	Narr	
TEB	IA	^{US-} 6,013,647	01-11-2000	Heinisch	
728	IВ	US- 2002-0111355-A1	08-15-2002	Zhang	
TEB	IC	us- 2004-0006122-A1	01-08-2004	Fensome	
TER	ID	US- 2004-0014798-A1	01-22-2004	Fensome	
FB	IE	US- 2004-0002535-A1	01-01-2004	Fensome	
TEB	IF	US- 2004-0006060-A1	01-08-2004	Fensome	
788	IG	US- 2003-0083322-A1	05-01-2003	Kraemer	

		FORE	IGN PATENT DOCU	MENTS		
	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	⊤ 6
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
TEB	EL	RU-95121739-A	02-10-1998	Buzzetti		
128	EM	RU-2073671-C1	02-20-1997	Ehrgott		
400	EN	RU-2165925	04-27-2001	Hewawasam		
100	EO	WO-95/04048	02-09-1995	Levi		
100	EP	WO-86/03749	07-03-1986	Kuhla		
426	EQ	WO-91/04974	04-18-1991	von der Saal		

Examiner Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1,97 and 1,98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Translation is attached.

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 6

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	mplete if Known	
Application Number	10/767,813	
Filing Date	January 29, 2004	
First Named Inventor	Zhang et al.	
Art Unit	unassigned / L/Y	
Examiner Name	unassigned BETTON, T.E.	
Attorney Docket Number	AHPWA1DUSA	

			U. S. PATENT D	OCUMENTS (S	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevan
		Number-Kind Code ² (# known)			Figures Appear
		US-	ļ		
		US-			<u>-</u>
		US-			
		US-	·		
		US-			*
		US-			
	-	US-			
		US-			
		US-			
	-	US-	1		
	_	US-			
	 	US-			
		US-			
· · · · · · · · · · · ·	\vdash	US-			
		US-			
	 	US-	 		

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	_
		Country Code ³ "Number ⁴ "Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Ļ
KB	FL	WO-91/06545	05-16-1991	von der Saal		<u> </u>
20	FM	WO-93/12085	06-24-1993	Boar		_
JAP.	FN	WO-94/14434	07-07-1994	Elliott		<u> </u>
143	FO	WO-94/29272	12-22-1994	Boar	<u> </u>	
FEB	FP	WO-95/11013	04-27-1995	Chwalisz		
1/1/3		WO-95/20389	08-03-1995	Young		

Examiner Signature	7 in 6 2000	Date Considered	08/14/07
EXAMINER:	Initial if reference/considered, whether or not citation is in conformance with MPEP 609. Dra	w line through	citation if not in conformatice and not ber (optional). 2 See Kinds Codes of

considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the spriportate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 7

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	Complete if Known				
Application Number	10/767,813				
Filing Date	January 29, 2004				
First Named Inventor	Zhang et al.				
Art Unit	unassigned /614				
Examiner Name	unassigned BETTON, T.E.				
Attorney Docket Number	AHPWA1DUSA				

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
		US-	<u> </u>	<u> </u>	030
		US-			
		US-			•
		US-	·		
		US-			
		US-			
	<u> </u>	US-			
		US-			
	 	US-			
		US-			
		US-			
	\vdash	US-			

		FORE	IGN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	٠,
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-OD-YYYY		Or Relevant Figures Appear	<u> </u>
123	GL	WO-95/20972	08-10-1995	Hodgen		<u> </u>
1/3/5	GM	WO-95/33746	12-14-1995	Kamireddy		
100	GN	WO-96/15794	05-30-1996	Spicer		<u> </u>
Kak	GO	WO-96/19458	06-27-1996	Jones		<u> </u>
seh	GP	WO-96/19997	07-04-1996	Chwalisz	·	╙
100	GQ	WO-97/13767	04-17-1997	Binder		ΙV

Examiner Signature	June hellon	Date Considered	08/14/67

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usfio.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is stached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/767,813 January 29, 2004 Filing Date INFORMATION DISCLOSURE First Named Inventor Zhang et al. STATEMENT BY APPLICANT Art Unit unassigned /6/U UDassigned RETION. AHPWA1DUSA (Use as many sheets as necessary) **Examiner Name**

Attorney Docket Number

			U. S. PATENT	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (# known)}	1:		rigules Appeal
		US-			
		US-			
	<u> </u>	US-			
	—	US-	1.		
		US-			
	 	US-			
		US-			
		US-			
		US-			
	-	US-			
		US-			
	├	US-			
	 	US-	- 		
	 	US-			
	 	US-		,	
	├	US-			
	+	US-			
	├	US-			
	├	US-			

		FORE	IGN PATENT DOCU	MENTS		,
	Cite No.	e Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	ا ہا
7	7	Country Code ³ "Number ⁴ "Kind Code ⁸ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	
KK	HL	WO-97/49407	12-31-1997	Coelingh Bennin		
122	нм	WO-98/14436	04-09-1998	Christ		
	γHN	WO-98/27059	06-25-1998	Kurihara		
153	но	WO-98/55116	12-10-1998	Goulet		
1/2/18		WO-99/10325	03-04-1999	McNutt		
		WO-99/11264	03-11-1999	Widdowson		

Examiner Signature	mx 2 Zetto		08/14/07
considered. USPTO Pate	i: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Dri Include copy of this form with next communication to applicant. Applicant's unique citation of ent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document atent documents, the indication of the year of the reign of the Emperor must precede the serial rate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applica	t by the two-lett number of the pa	ter code (WIPO Standard ST.3). 4 For

Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, use of the properties of the complete displication form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete II Known				
Application Number	10/767,813			
Filing Date	January 29, 2004			
First Named Inventor	Zhang et al.			
Art Unit	unassigned 1614			
Examiner Name	unassigned BETTON, T.E.			
Attorney Docket Number	AHPWA1DUSA	_		

Considered

Cuanina-	Cite	Desument Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Document Number	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant
		Number-Kind Code ^{2 (F known)}			Figures Appear
		US-			
		US-	,		
		US-		•	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
	-	US-	<u> </u>		
		US-			
		US-			
		US-			

		FORE	IGN PATENT DOCL	MENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	۔ ا
	,	Country Code ³ Number ⁴ 'Kind Code ⁸ (# known)	·	Or Relevant Figures Appear	Ľ	
100	IL	WO-99/15500	04-01-1999	Davis		_
18 B	IM	WO-99/44608	09-10-1999	Ramachandran		┞-
1						L
						⊬
				,		┡

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with (part communication to applicant: Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspic.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known
Substitute	for form 1	449B/PTO		Application Number	10/767,813
INF	ORMAT	TION	DISCLOSURE	Filing Date	January 29, 2004
STA	TEME	NT BY	APPLICANT	First Named Inventor	Zhang et al.
i				Group Art Unit	unassigned 1614
	(Use as many sheets as necessary)			Examiner Name -	unassigned BETTON, T.E.
Sheet	10	of	15	Attorney Docket Number	AHPWA1DUSA

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
NB	AR	ANDREANI et al., "Potential antitumor agents XVII(1). Cytotoxic agents from indole derivatives and their intermediates", Acta. Pharm. Nord. 1990 2(6):407-414	
158	AS	ARNDT et al., "New Heterocycle substituted Benzo-Fused Azine and Azole Derivatives - Useful as Selective Herbicides for Pre or Post-Emergence Application", October 10, 1988 Derwent WPI Abstract EP 311135	
14h	AT	BARENGOLTS et al., "Progesterone antagonist RU486 has bone-sparing effects in ovariectomized rats", <i>Bone July</i> 1995 17(1):21-25	
143	AU	BARTSCH, et al., "3-Amino ethyl benzoxazine derivs - useful for the prevention and treatment of cerebral disorders such as senile dementia", November 10, 1995 Derwent WPI abstract of Russian Patent No. RU 94007350	
143	AV	BRUMAGNIEZ et al., "Benzimidazole and Azabenzimidazole(s) - Having Cardiotonic, Vasodilating, Anti-Hypertensive, Anti-Aggregation, and Anti-Ulcer Activity", February 27, 1990 Derwent WPI Abstract EP 385850	
14/3	AW	BUZZETTI et al., "3-(Bicyclylmethylene)oxindole antiangiogenic agents", November 19, 1996 Abstract of US Patent No. 5,576,330	
760	AX	CANONNE et al., "Spirocyclization of 1-(o-Aminophenyl)cycloalkanols and 1-(2'-Amino-3'-pyridinyl)cycloalkanols", J. Heterocyclic Chem. January-February 1989 26:113	
Post	AY	CHEN et al., "Synthesis and SAR of a novel series of spirobenzothlzaepine derivatives with antiprogestin activity", POI-37, 16 th Int. Cong. Het. Chem., Montana 1997	
Tes	AZ	CHIARINO et al., "2,1-Benzisothiazoline 2,2-Dioxide and derivatives", J. Heterocycl. Chem. Noyember-December 1986 23(6):1645-1649	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with fiext communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner

Signature

Date

Considered

			Complete if Known		
Substitute for form 1449B/PTO		Application Number	10/767,813		
INF	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	January 29, 2004
STA				First Named Inventor	Zhang et al.
				Group Art Unit	unassigned 1614
	(Use as many sheets as necessary)		Examiner Name	unassigned FETTON, T.E.	
Sheet	T 11	of	15	Attorney Docket Number	AHPWA1DUSA '

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
	BR	CHWALISZ et al. "Contraceptive Pack for Implantation Inhibition - Contains	
111		Competitive Progesterone Antagonist and Gestagen for Sequential Oral	
147		Administration.", June 29, 1995 Derwent WPI Abstract DE 4,344,463	
-1-0-	BS	CHWALISZ et al. "Female Contraceptive Method Comprises Gestation Treatment	
1503		with Intermittent Progesterone Antagonist Administration.", March 9, 1995 Derwent WPI Abstract DE 4,330,234	
100	BT	CLEMENCE et al., "New 4-(amino-alkoxy-phenyl-methyl)1H-indole derivatives",	
161	ν.	October 10, 1996 Abstract of Russian Patent No. 2067576	
1-0	BU	COMBS et al., "Heteroatom analogues of bemoradan: Chemistry and cardiotonic	
11:0		activity og 1,4-Benzothiazinylpyridazinones", J. Med. Chem. January 1992 35:172-	
12/		176	
1.0	BV	COMBS et al., "Nonsteroidal progesterone receptor ligands. 2. High-affinity ligands	
16%	DV	with selectivity for bone cell progesterone receptors", J. Med. Chem. December 8, 1995 38:4880	
100	BW	Derwent WPI Abstract, "New Imidazo-Pyridine Derivatives - Useful as Platelet	
00	.	Agglutination Inhibitor, Antiallergic, Antiinflammatory Sedative, Cardiac, and	1
17/4		Cardiovascular Vasodilators", May 17, 1988 JP 63112584	
$\mu \nu \nu$	BX	EDWARDS et al., "5-Aryl-1,2-Dihydro-5H-Chromeno[3,4-f]Quinolines as potent,	
-16	2	orally active, nonsteroidal progesterone receptor agonists: The effect of D-ring	
1456		substituents", J. Med. Chem. January 29, 1998 41:303-310	<u> </u>
14	BY	EHRGOTT et al., "New 1,3-disubstituted-2-oxo-indole derivatives", February 20,	
0411	~ .	1997 Abstract of Russian Patent No. 2073671	
1 all	BZ	EVANS, "The steroid and thyroid hormone receptor superfamily", Science May 13,	
791		1988 240(4854):889-895	

Date Examiner Considered Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain, a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute	for form 1449	9В/РТО		Application Number	10/767,813		
INFO	ORMATI	ON	DISCLOSURE	Filing Date	January 29, 2004		
			APPLICANT	First Named Inventor	Zhang et al.		
				Group Art Unit	unassigned 1614		
(Use as many sheets as necessary)				Examiner Name	unassigned BETTON, T.E.		
Sheet	12	of	15	Attorney Docket Number	AHPWA1DUSA		

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
75/3	CR	FENSOME et al., "New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles". Bio. & Med. Chem. Lett. December 2, 2002 12(23):3487-3490	
FLE	CS	FENSOME et al., "Novel 5-aryl-1,3-dihydro-indole-2-thiones: Potent, orally active progesterone receptor agonists", Bio. & Med. Chem. Lett. April 7, 2003 13(7):1317-1320	
7.58	CT	FOREST et al., "A novel class of cardiotonic agents: Synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties", J. Med. Chem. January 1992 35:163-172	
790	CU	GROMACHEVSKAYA et al., "Studies of 4H-3,1-Benzoxazines", Chem. Hetercycl.	
7503	CV	HAMANN et al., "Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists". Ann. N.Y. Acad. Sci. June 12, 1995 761:383-387	
7.58	CW	HARTMANN et al., "Effects of brofoxine, a new anxiolytic on experimentally induced conflict in rats" Proc. West. Pharmacol. Soc. 1978 21:51-55	
750	CX	HEWAWASAM et al., "New 3-Phenyl oxindole derivatives", April 27, 2001 Abstract of Russian Patent No. 2165925	
75/3	CY	HORWITZ et al., "Progestin, progesterone receptors, and breast cancer", Hormone Cancer, (Vedeckis ed.) Birkhaeuser: Boston, Massachusetts 1996 pp. 283-306 (abstract)	
THIS	CZ	KEKKONEN et al., "Sequential regiment of the antiprogesterone RU486 and synthetic progestin for contraception", Fertility and Sterility October 1993 60(4):610-615	_
7295	DR	KENDE et al., "Regioselective C-3 alkylation of oxindole dianion", Synth. Commun. 1982 12(1):1	

Examiner	Sunotto & Billing	Date Considered	08/19	10-1	
Signature					
	7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7		/ /	′ /	
	Life and an agrid and whether or not citation is in conformance will	L MOCO COO Describes the	nuch effation il	f not in conformance and	not
A MARKA SATSING . Talkini	uiss admidared whiches or not citation is in conformance wil	IN MPER DUY. DIAW IIIR UII	gogii Glauon ii	HOL III COMPANIONEC COS	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to piace a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			Complete if Known		
Substitute	e for form 1	449B/PTO		Application Number	10/767,813
INF	ORMA	rion	DISCLOSURE	Filing Date	January 29, 2004
STA	STATEMENT BY APPLICANT		First Named Inventor	Zhang et al.	
				Group Art Unit	unassigned (6/4
	(Use as many sheets as necessary)			Examiner Name	-unassigned BETTON, T.E.
Sheet	13	of	15	Attorney Docket Number	AHPWA1DUSA

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	DS	KETTEL et al., "Endocrine responses to long-term administration of the	
757		antiprogesterone RU486 in patients with pelvic endometriosis", Fertility and Sterility September 1991 56(3):402-407	
108	DT	KOLASA et al., "Preliminary Pharmacological Studies of the Central Action of Phenyl	
7501	Di	and Piperidinomethyl Derivatives of 2-Benzoxazolone", Chemical Abstracts July 4,	
190	- DII	1983 Vol. 99, No. 1, Abst. No. 157a KOVEMAN, et al., "Condensed heterocyclic ring structure compounds used organic	
l ,	DU	luminophores, etc comprises 2, 3- dihydro-pyrido-1, 2, 3-de-1, 4-benzoxazine	
6		luminophores, etc comprises 2, 3- dinydro-pyrido-1, 2, 3-dc-1, 4-betreet of Russian	
120		chloride and its derivatives ", December 27, 1997 Derwent WPI abstract of Russian Patent No. RU 2100359	
226	DV	KUMAR et al., "Synthesis of 7-Azaindole and 7-Azaxindole derivatives through a	
1513	,	palladium-catalyzed cross-coupling reaction", J. Org. Chem. 1992 57(25):6995-6998	ļ
000	DW	KURIHARI et al., "Synthesis of (+)-PF1092A, B, and C; New nonsteroidal	
145		progesterone receptor ligands", J. Antibiotics April 1997 50(4):360	
	DX	MAMAEV et al., "Synthesis of 4H-Thieno [3,2-B] Pyrrol-5(6H)-One" Bulletin of the	
24		Academy of Sciences on the USSR. Division of Chemical Science, US, Consultants	
12-15		Bureau. 1966 New York. Vol. 9, p. 1549-1553	
 	DY	MEANWELL et al., "Regiospecific Functionalization of 1,3-dihydro-2H-	
Deta		Benzimidazol-2-One and Structurally Related Cyclic Urea Derivatives", J. Organic	
120		Chem. March 24, 1995 60(6):1565-1582	
71	DZ	MICHNA et al., "Differentiation therapy with progesterone antagonists", Ann. N.Y.	
12B		Acad. Sci. June 12, 1995 761:224-247	
1	ER	MURPHY et al., "Regression of uterine leiomyomata in response to the	
1253		antiprogesterone RU486", J. Clin. Endo. Metab. February 1993 76(2):513-517	1

Examiner Signature	Temoth E. Betton	Date Considered	08/14/07	

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not EXAMINER: Initial if reference donsidered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformatic and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 144			Complete if Known			
Substitute	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/767,813			
INF	ORMA	TION	DISCLOSURE	Filing Date	January 29, 2004	
		First Named Inventor	Zhang et al.			
				Group Art Unit	unassigned /6/4	
(Use as many sheets as necessary)			as necessary)	Examiner Name	unassigned RETTUR, T. E.	
Sheet	14	of	15	Attorney Docket Number	AHPWA1DUSA	

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Va	ES	NARR et al., "Preparation, testing, and formulation of Imidazobenzoxazinones as	
111		cardiotonics", Chemical Abstracts 1988 109:22973	├┤
	ET	PERLMAN et al., "20-Oxopregnacalciferols: Vitamin D Compounds that bind the	
1415		progesterone receptor", Tet. Letters 1994 35(15):2295	\vdash
100	EU	PFLEGEL et al., "Polarografie con 7-Chlor-5-phenly-2-thioxo-1H-2,3-dihydro-1,3,4-	
199		benzotriazepinen", Pharmazie 1982 37(10):714-717	
200	EV	SAKATA et al., "Silver halide photographic materials useful for platemaking", Chemical	1 1
(F26)		Abstracts 1993 123:301431	
non	EW	SINGH et al., "An Efficient and Novel Synthesis of Fused Thiazol-2(3H)-ones"	•
120		Heterocycles January 1993 36(1):133-134	
	EX	SINGH et al., "Novel cAMP PDE III inhibitor Imidazo[4,5-b]pyridin-2(3H)-ones and	
1763		Thiazolo[4,5-b]pyridin-2(3H)-ones and their analogs", J. Med. Chem. January 21, 1994	
W		37:248	
	EY	TUCKER et al., "Synthesis of a series of 4-(Arylethylnyl)-6-Chloro-4-Cyclopropyl-3,4-	
206	·	dihydroquinazolin-2(1H)-ones as novel non-nuceloside HIV-1 reverse transcriptase	
val		inhibitors", J. Med. Chem. July 22, 1994 37:2347-2444	\sqcup
11 h	EZ	TURCK et al., "On the metabolism of 3-substituted and 3,6-disubstituted pyridazines",	
123		Tetrahedron 1993 49(3):599-606	
Ach	FR	ULMANN et al., "Clinical uses of mifepristone (MFP)", Ann. N.Y. Acad. Sci. June 12,	
199		1995 261:248	
	FS	VERNIN et al., "Etude Dans la Serie des Radicaux Heterocycliques. Partie XV.	
100	Ì	Decomposition aprotique de 1' amino-6-ethyl-2-benzothiazole dans des substrats	
12-11		aromatiques et heteroaromatiques: preparation des mesityl-6- et furyl-6-ethyl-2-	
		benzothiazoles, des sels quaternaires et des spiropyrannes correspondants", Helvetica	
		Chimica Acta January 24, 1979 62(1/3):21-30	Ш

Considered Signature * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner

Date

EXAMINER: Initial if reference considered, Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitut	INFORMATION DISCLOSURE		Application Number	10/767,813		
INF	ORMAT	TION I	DISCLOSURE	Filing Date	January 29, 2004	
STA	STATEMENT BY APPLICANT			First Named Inventor	Zhang et al.	
				Group Art Unit	unassigned /6/4	
(Use as many sheets as necessary)		Examiner Name	unassigned BETTEN, T.G.			
Sheet	15	of	15	Attorney Docket Number	AHPWAIDUSA	

		NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	publisher, city and/or country where published				
746	FT	ZHI et al., "5-Aryl-1,2-Dihydrochromeno[3,4-f]quinolines: A novel class of nonsteroidal human progesterone receptor agonists", J. Med. Chem. January 29, 1998 41(3):291-302				
l						
· · · · · · · · · · · · · · · · · · ·						
		·	-			
			<u></u>			

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered

Signature